Cytokinetics (NASDAQ:CYTK – Get Rating) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.24) by ($0.14), Briefing.com reports. The company had revenue of $4.60 million for the quarter, compared to analyst estimates of $2.50 million. Cytokinetics had a negative return […]
Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) CEO Robert I. Blum sold 12,500 shares of the business’s stock in a transaction that occurred on Friday, April 28th. The shares were sold at an average price of $37.68, for a total value of $471,000.00. Following the completion of the sale, the chief executive officer now owns 441,058 […]
ProShare Advisors LLC raised its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) by 8.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 21,149 shares of the biopharmaceutical company’s stock after purchasing an additional 1,615 shares during the period. ProShare Advisors LLC’s […]
Several brokerages have updated their recommendations and price targets on shares of Cytokinetics (NASDAQ: CYTK) in the last few weeks: 4/3/2023 – Cytokinetics had its price target lowered by analysts at Cantor Fitzgerald from $61.00 to $59.00. They now have an “overweight” rating on the stock. 4/3/2023 – Cytokinetics had its price target lowered by […]
China Universal Asset Management Co. Ltd. trimmed its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) by 96.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 961 shares of the biopharmaceutical company’s stock after selling 27,087 shares during the period. China […]